Clinical Trial Results:
Open-label, multi-center, two-stage, age stratified, pharmacokinetic, safety, and efficacy study in children 2 months to < 2 years of age undergoing Magnevist Injection enhanced MRI
Summary
|
|
EudraCT number |
2009-013081-17 |
Trial protocol |
DE |
Global end of trial date |
09 Sep 2010
|
Results information
|
|
Results version number |
v1 |
This version publication date |
12 Jul 2016
|
First version publication date |
25 Jul 2015
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
BAY86-6661/91784
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00937391 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Study number: 312046 | ||
Sponsors
|
|||
Sponsor organisation name |
Bayer HealthCare AG
|
||
Sponsor organisation address |
Kaiser-Wilhelm-Allee, Leverkusen, Germany, D-51368
|
||
Public contact |
Therapeutic Area Head, Bayer HealthCare AG, clinical-trials-contact@bayerhealthcare.com
|
||
Scientific contact |
Therapeutic Area Head, Bayer HealthCare AG, clinical-trials-contact@bayerhealthcare.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
Yes
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Dec 2010
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Sep 2010
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
1. To determine the optimal efficacious dose [0.05 millimoles per kilogram body weight (mmol/kg BW) or 0.1 mmol/kg BW) of Magnevist injection in Stage 1.
2. To evaluate pharmacokinetics (PK) of Magnevist injection at the optimal efficacious dose from Stage 1 in this population in Stage 2.
|
||
Protection of trial subjects |
To take into account that this clinical trial enrolled children, the following specific ethical considerations
and provisions were followed:
1. Minimized as far as feasible the number of pediatric study subjects and examinations to allow for meaningful assessment of PK parameters (the primary objective of this trial)
2. Employed population based PK approach allowing sparse sampling for PK analysis [according to International Conference on Harmonization Efficacy module 11 (ICH E11)]
3. Employed for PK measurements, a sensitive analytical assay requiring only small blood samples and a laboratory experienced with handling small volume samples for safety (in accord with ICH E11)
4. Drew volumes of blood as low as feasible for safety and PK investigations [that is, total sample volumes for safety and PK assessments about 4 to 5 milliliter (mL)]
5. Used indwelling catheters rather than multiple venous punctures whenever feasible and considered topical anesthesia where catheter was placed
6. Minimized, in general, any discomfort, inconvenience, pain, fright, and time of separation from parents or familiar surroundings
7. Provided a child friendly and familiar environment
8. Ensured that only Investigators and staff with pediatric experience participated in this study.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
21 Jan 2010
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety | ||
Long term follow-up duration |
1 Months | ||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Germany: 48
|
||
Country: Number of subjects enrolled |
United States: 6
|
||
Worldwide total number of subjects |
54
|
||
EEA total number of subjects |
48
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
54
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
The date of the first subject, first visit was 21 January 2010. The date of the last subject, last visit was 09 September 2010. The date of the Blinded Read for Stage 1 was 27 April 2010. The date of the Blinded Read for Stage 2 was 08 September 2010. | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
A subject was enrolled in either Stage 1 or Stage 2 and not both. Overall for both stages, 61 subjects were screened, 7 were screen failures, and 54 were enrolled and treated of which 53 subjects completed the study (20 unique subjects in Stage 1 and 33 unique subjects in Stage 2). | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Non-randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1 | |||||||||||||||
Arm description |
Subjects received an intravenous (IV) injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine. Upon completion of the magnetic resonance (MR) imaging, the subjects received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Gadopentetate dimeglumine
|
|||||||||||||||
Investigational medicinal product code |
BAY86-6661
|
|||||||||||||||
Other name |
Magnevist
|
|||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Subjects received an IV injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine. Upon completion of the MR imaging, the subjects received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW).
|
|||||||||||||||
Arm title
|
Gadopentetate dimeglumine (Magnevist, BAY86-6661) – Stage 2 | |||||||||||||||
Arm description |
Subjects received the optimal efficacious dose established in Stage 1 as a single IV injection of gadopentetate dimeglumine [0.1 mmol/kg BW (0.2 mL/kg BW)]. | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Gadopentetate dimeglumine
|
|||||||||||||||
Investigational medicinal product code |
BAY86-6661
|
|||||||||||||||
Other name |
Magnevist
|
|||||||||||||||
Pharmaceutical forms |
Injection
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Subjects received the optimal efficacious dose established in Stage 1 as a single IV injection of gadopentetate dimeglumine [0.1 mmol/kg BW (0.2 mL/kg BW)].
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received an intravenous (IV) injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine. Upon completion of the magnetic resonance (MR) imaging, the subjects received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Gadopentetate dimeglumine (Magnevist, BAY86-6661) – Stage 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received the optimal efficacious dose established in Stage 1 as a single IV injection of gadopentetate dimeglumine [0.1 mmol/kg BW (0.2 mL/kg BW)]. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1
|
||
Reporting group description |
Subjects received an intravenous (IV) injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine. Upon completion of the magnetic resonance (MR) imaging, the subjects received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). | ||
Reporting group title |
Gadopentetate dimeglumine (Magnevist, BAY86-6661) – Stage 2
|
||
Reporting group description |
Subjects received the optimal efficacious dose established in Stage 1 as a single IV injection of gadopentetate dimeglumine [0.1 mmol/kg BW (0.2 mL/kg BW)]. | ||
Subject analysis set title |
Primary Analysis Set (PAS)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
In order to ensure that there would be 5 valid subjects per age group, more than 5 subjects were enrolled in Stage 1. The determination of the optimal dose was based on 5 valid subjects per age group. Therefore, the PAS (N=15) was defined as an additional analysis set, consisting of the first 5 PPS subjects of each age group (sorted by date of enrollment). The PAS was used for the determination of the optimal efficacious dose in Stage 1 only.
|
||
Subject analysis set title |
Stage 1 (Unenhanced Image)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects (N=20) for whom unenhanced image was taken before administering any injection in Stage 1.
|
||
Subject analysis set title |
Gadopentetate Dimeglumine - Stage 1 and 2
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Stage 1: All subjects who received the appropriate dose of gadopentetate dimeglumine injection based on kg BW.
Stage 2: Subjects who received plus or minus (+/-) 10% of the appropriate dose of gadopentetate dimeglumine injection based on kg BW and had values for both PK samples.
Overall, this reporting group consisted of 44 subjects.
|
||
Subject analysis set title |
Full analysis set (FAS) - Total
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
FAS (N=54) for safety and for efficacy included all subjects who received any amount of the investigational product.
|
||
Subject analysis set title |
Per Protocol Set (PPS)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
PPS defined for Stage 1 as all 18 subjects who received the appropriate dose of gadopentetate dimeglumine Injection based on kg BW and in Stage 2 as 26 subjects who received +/- 10% of the appropriate dose based on kg BW and had values for both PK samples.
|
||
Subject analysis set title |
Stage 2 (Combination Image)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects (N=34) received the optimal efficacious dose established in Stage 1 as a single IV injection of gadopentetate dimeglumine [0.1 mmol/kg BW (0.2 mL/kg BW)].
|
||
Subject analysis set title |
Stage 2 (Unenhanced Image)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects (N=34) for whom unenhanced image was taken before administering any injection in Stage 2.
|
||
Subject analysis set title |
Stage 1 (Combination Image 0.1 mmol/kg)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects (N=20) received an IV injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine.
|
||
Subject analysis set title |
Stage 1 (Combination Image 0.05 mmol/kg)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Subjects (N=20) received an IV injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine.
|
||
Subject analysis set title |
Pharmacokinetic Analysis Set (PKS)
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
PKS (N=44) was based on the PPS defined for Stage 1 as all subjects (N=18) who received the appropriate dose of gadopentetate dimeglumine injection based on kg BW and in Stage 2 as those subjects (N=26) who received +/- 10% of the appropriate dose based on kg BW and had values for both PK samples.
|
|
||||||||||||||||
End point title |
Number of Subjects With Diagnostic Adequacy - Open-label Clinical Investigator (CI) (Per Protocol Set) [1] | |||||||||||||||
End point description |
A clinical judgment by the open-label CIs as to whether ("yes") or not ("no") the CI could make a diagnosis from the image.
|
|||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
||||||||||||||||
|
||||||||||||||||
Notes [2] - Only first 3 subjects of Stage 1 received 2 IV injections of 0.05 mmol/kg BW. [3] - Only first 3 subjects of Stage 1 received 2 IV injections of 0.05 mmol/kg BW. |
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||
End point title |
Dose Determined by Blinded Readers (BR) to be Superior for Diagnosis [4] | ||||||||||||||||||
End point description |
Dose superiority was a calculation based upon the BRs' assessment of 4 visualization parameters.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||
Notes [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||||||||||||
|
|||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Paired-dose Comparison of Number of Subjects With Dose Superiority Determined for 4 Lesion Visualization Variables - Blinded Readers (BRs) [5] | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
For each subject, the BR indicated which dose had better contrast enhancement, better border delineation, clearer internal morphology, and provided more diagnostic information. The dose chosen for 3 or 4 of these variables was the selected dose for that BR and subject. If each dose was superior on 2 variables, the dose which provided more diagnostic information was selected for that subject. The dose selected for the majority of subjects was the dose selected by that BR; if chosen by 2 or 3 BRs, it was the selected dose.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||||||||||||||||||||||||||
Notes [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Notes [6] - PAS. [7] - PAS. |
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetic Analysis - Total Clearance (CL) [8] | ||||||||
End point description |
Total clearance is the fraction of the volume of distribution (Vd) which is completely purified per unit of time and depends also on the plasma half-life of the drug.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
20 to 45 min and 4 to 8 hours post injection
|
||||||||
Notes [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||
|
|||||||||
Notes [9] - PKS. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetic Analysis - Total Clearance (CL)/Body Weight (BW) [10] | ||||||||
End point description |
CL/BW = total clearance normalized by BW.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
20 to 45 min and 4 to 8 hours post injection
|
||||||||
Notes [10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||
|
|||||||||
Notes [11] - PKS. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetic Analysis - Volume of Distribution at Steady State (Vss) [12] | ||||||||
End point description |
Vss is an estimate of drug distribution independent of the elimination process and is proportional to the amount of drug in the body versus the drug plasma concentration at steady-state.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
20 to 45 min and 4 to 8 hours post injection
|
||||||||
Notes [12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||
|
|||||||||
Notes [13] - PKS. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetic Analysis - Volume of Distribution at Steady State (Vss) /Body Weight (BW) [14] | ||||||||
End point description |
PK Analysis - Volume of Distribution at Steady State (Vss) /Body Weight (BW).
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
20 to 45 min and 4 to 8 hours post injection
|
||||||||
Notes [14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||
|
|||||||||
Notes [15] - PKS. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetic Analysis - Area Under the Drug Concentration-time Curve (AUC) [16] | ||||||||
End point description |
AUC = Area under the drug concentration-time curve from administration to infinity.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Samples taken 20 to 45 min and 4 to 8 hours post injection. AUC calculated from time of injection to infinity.
|
||||||||
Notes [16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||
|
|||||||||
Notes [17] - PKS. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Pharmacokinetic Analysis - Terminal Elimination Half life (t1/2) [18] | ||||||||
End point description |
t1/2 = termination elimination half-life calculated from the area under the drug concentration-time curve from administration to infinity.
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
Samples taken at 20 to 45 min and at 4 to 8 hours post injection; t1/2 calculated from area under the drug concentration-time curve from administration to infinity
|
||||||||
Notes [18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics were done, no inferential statistical analyses were performed. |
|||||||||
|
|||||||||
Notes [19] - PKS. |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Number of Lesions Detected - Stage 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The BRs and the open-label Clinical Investigators determined the number of subjects with 0, 1, 2, and 3 or more lesions.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [20] - FAS. [21] - FAS. [22] - FAS. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Number of Lesions Detected - Stage 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the number of subjects with 0, 1, 2, and 3 or more lesions.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [23] - FAS. [24] - FAS. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Quality of Lesion Visualization - Stage 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the quality of lesion visualization with the unenhanced and the combined image sets based on a 3-point scale (1=excellent - lesion clearly seen and diagnosis possible; 2=fair but adequate - most of lesion seen and diagnosis possible; and 3=poor - lesion barely seen and diagnosis not possible).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [25] - FAS. [26] - FAS. [27] - FAS. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Quality of Lesion Visualization - Stage 2 | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the quality of lesion visualization with the unenhanced and the combined image sets based on a 3-point scale (1=excellent - lesion clearly seen and diagnosis possible; 2=fair but adequate - most of lesion seen and diagnosis possible; and 3=poor - lesion barely seen and diagnosis not possible).
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Notes [28] - FAS. [29] - FAS. |
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Quality of Border Delineation - Stage 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the quality of border delineation based on a 3-point scale (1=excellent - border completely delineated; 2=fair but adequate - some of the border is delineated; and 3=poor - entire or almost the entire border is not delineated) by image set.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [30] - FAS. [31] - FAS. [32] - FAS. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Quality of Border Delineation - Stage 2 | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the quality of border delineation based on a 3-point scale (1=excellent - border completely delineated; 2=fair but adequate - some of the border is delineated; and 3=poor - entire or almost the entire border is not delineated) by image set.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Notes [33] - FAS. [34] - FAS. |
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Most Frequent Diagnostic Findings With Unenhanced Images - Stage 1 [35] | ||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the most frequent diagnostic findings with the unenhanced images.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||
Notes [35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 2, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1". |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
Notes [36] - FAS. |
|||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||
End point title |
Most Frequent Diagnostic Findings With Unenhanced Images - Stage 2 | ||||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the most frequent diagnostic findings with the unenhanced images.
|
||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||
|
|||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
Overall Number of Subjects With Change in Diagnosis From Unenhanced to Combined Images - Stage 1 | |||||||||||||||||||||
End point description |
The BRs and the open-label CIs determined the number of subjects with a change in diagnosis from unenhanced to combined images.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [37] - FAS. [38] - FAS. |
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
End point title |
Overall Number of Subjects With Change in Diagnosis From Unenhanced to Combined Images - Stage 2 [39] | ||||||||||||||
End point description |
The BRs and the open-label CIs determined the number of subjects with a change in diagnosis from unenhanced to combined images.
|
||||||||||||||
End point type |
Secondary
|
||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||
Notes [39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 2, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1". |
|||||||||||||||
|
|||||||||||||||
Notes [40] - FAS. |
|||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Specific Change in the Diagnosis From Unenhanced to Combined Images - Stage 1 | ||||||||||||||||||||||||||||||||||||||||||
End point description |
Those subjects for whom the diagnosis changed for at least 1 BR from unenhanced to combined images are presented for Stage 1. For completeness, the corresponding data for these subjects are presented for the open-label CIs.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Notes [41] - FAS. [42] - FAS. |
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Specific Change in the Diagnosis From Unenhanced to Combined Images - Stage 2 [43] | ||||||||||||||||||||||||||||||||||||||||||
End point description |
Those subjects for whom the diagnosis changed for at least 1 BR from unenhanced to combined images are presented for Stage 2. For completeness, the corresponding data for these subjects are presented for the open-label CIs.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||||||||||||||||||||||
Notes [43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 2, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1". |
|||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Notes [44] - FAS. |
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Diagnostic Confidence - Stage 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
The overall diagnostic confidence of the BRs and the open-label CIs was indicated on a 3-point scale: 1=not confident; 2=confident; and 3=very confident.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [45] - FAS. [46] - FAS. [47] - FAS. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
End point title |
Number of Subjects With Diagnostic Confidence - Stage 2 | |||||||||||||||||||||||||||||||||||||||||||||
End point description |
The overall diagnostic confidence of the BRs and the open-label CIs was indicated on a 3-point scale: 1=not confident; 2=confident; and 3=very confident.
|
|||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Notes [48] - FAS. [49] - FAS. |
||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Management Based on Unenhanced Images - Stage 1 [50] | ||||||||||||||||
End point description |
For Stage 1 based on unenhanced images, the recommended management is presented as determined by the open-label CIs.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Within 5 minutes before injection
|
||||||||||||||||
Notes [50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 1, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 2". |
|||||||||||||||||
|
|||||||||||||||||
Notes [51] - FAS with only subjects for whom information on management was given. |
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||
End point title |
Management Based on Unenhanced Images - Stage 2 [52] | ||||||||||
End point description |
For Stage 2 based on unenhanced images, the recommended management is presented as determined by the open-label CIs.
|
||||||||||
End point type |
Secondary
|
||||||||||
End point timeframe |
Within 5 minutes before injection
|
||||||||||
Notes [52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 2, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1". |
|||||||||||
|
|||||||||||
Notes [53] - FAS with only subjects for whom information on management was given. |
|||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Overall Number of Subjects With Change in Management From Unenhanced to Combined Images - Stage 1 | |||||||||
End point description |
For Stage 1, the number of subjects for whom the recommended management of the open-label CIs changed from unenhanced to combined images is presented for both doses.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||
|
||||||||||
Notes [54] - FAS. [55] - FAS. |
||||||||||
No statistical analyses for this end point |
|
|||||||
End point title |
Overall Number of Subjects With Change in Management From Unenhanced to Combined Images - Stage 2 [56] | ||||||
End point description |
For Stage 2, the number of subjects for whom the recommended management of the open-label CIs changed from unenhanced to combined images is presented for the optimal efficacious dose determined in Stage 1.
|
||||||
End point type |
Secondary
|
||||||
End point timeframe |
Within 5 minutes after injection
|
||||||
Notes [56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 2, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1". |
|||||||
|
|||||||
Notes [57] - FAS. |
|||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||
End point title |
Number of Subjects With Specific Change in Management From Unenhanced to Combined Images - Stage 1 | |||||||||||||||||||||||||||
End point description |
The actual change in management from unenhanced to combined images recommended by the open-label CIs is presented for both doses in Stage 1.
|
|||||||||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
|||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Notes [58] - FAS. [59] - FAS. |
||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||
End point title |
Number of Subjects With Specific Change in Management From Unenhanced to Combined Images - Stage 2 [60] | ||||||||||||||||
End point description |
The actual change in management from unenhanced to combined images recommended by the open-label CIs is presented in Stage 2 for the optimal efficacious dose determined in Stage 1.
|
||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
Within 5 minutes after injection
|
||||||||||||||||
Notes [60] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Since this endpoint was analysed only in Stage 2, statistics were not reported for other arm in the baseline period, that is, "Gadopentetate dimeglumine (Magnevist, BAY86-6661) - Stage 1". |
|||||||||||||||||
|
|||||||||||||||||
Notes [61] - FAS. |
|||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From start of treatment up to 30 days after last dose (follow-up)
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
13.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Gadopentetate Dimeglumine - Stage 2
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received the optimal efficacious dose established in Stage 1 as a single IV injection of gadopentetate dimeglumine [0.1 mmol/kg BW (0.2 mL/kg BW)]. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Gadopentetate Dimeglumine - Stage 1
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received an IV injection of 0.05 mmol/kg BW (0.1 mL/kg BW) gadopentetate dimeglumine. Upon completion of the MR imaging, the subjects received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
Decimal places were automatically truncated if last decimal equals zero. |